-transparent.png){kind=logo}
Twelve, healthy fasting, subjects received 200 mg cimetidine orally either with water or 1 g sucralfate in a randomized, single dose, two-way crossover study. Blood samples were taken for 12 h and urine was collected for 24 h. Cimetidine in plasma and urine was analysed by HPLC. There was no significant difference between the two treatments in peak plasma concentration, time to peak plasma concentration, area under the plasma concentration-time curve and urinary excretion. The results indicate that sucralfate did not reduce the bioavailability of cimetidine.
Related Publications
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
January 1986,
Drug intelligence & clinical pharmacy,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
September 1984,
Pharmacological research communications,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
January 1989,
Biopharmaceutics & drug disposition,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
January 1987,
The American journal of gastroenterology,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
December 1984,
Military medicine,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
January 1982,
Therapie,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
May 1984,
Methods and findings in experimental and clinical pharmacology,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
December 1995,
Journal of pharmaceutical sciences,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
April 1991,
Journal of clinical pharmacology,
H Albin, and
G Vincon, and
M C Lalague, and
P Couzigou, and
M Amouretti
February 2000,
British journal of clinical pharmacology,
